啟明醫療(02500.HK)自主研發核心產品VenusA-Plus於中國獲批上市
啟明醫療(02500.HK)公布,公司自主研發的核心產品VenusA-Plus經導管人工主動脈瓣膜置換系統-可回收輸送系統已獲得中國國家藥品監督管理局批准上市。VenusA-Plus的臨床結果顯示,其複合終點事件發生率低於預先設定的目標界值,顯示出此產品良好的安全性、有效性和操控性。VenusA-Plus的上市將縮短臨床醫生的學習曲線,加快經導管主動脈瓣置換術在中國的發展普及。
啟 明醫療將持續致力於結構性心臟病治療性醫療器械的的研發和商業化,為患者提 供更為安全有效的臨床解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.